CNBX Pharmaceuticals Inc. (CNBX): Revenue
$0
Year ended 2025-08-31
$0
Trailing 12 months to 2026-05-31
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $0 | -100.0% | 2025-12-01, From 2024-09-01 |
| 2024-08-31 | $130.1K | -68.3% | 2025-12-01, From 2023-09-01 |
| 2023-08-31 | $410.2K | n/m | 2024-11-29, From 2022-09-01 |
| 2022-08-31 | $30.0K | n/a | 2023-11-30, From 2021-09-01 |
| 2021-08-31 | $0 | -100.0% | 2021-11-29, From 2020-09-01 |
| 2020-08-31 | $7.2K | -27.3% | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | $9.8K | +2.5% | 2020-11-04, From 2018-09-01 |
| 2018-08-31 | $9.6K | +68.9% | 2019-11-29, From 2017-09-01 |
| 2017-08-31 | $5.7K | -94.9% | 2018-11-29, From 2016-09-01 |
| 2016-08-31 | $112.5K | n/a | 2017-12-08, From 2015-09-01 |
| 2015-08-31 | $0 | n/a | 2016-12-13, From 2014-09-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| CNBX Pharmaceuticals Inc. (CNBX) | 2025-08-31 | $0 | -100.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $44.33B | +5.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $48.19B | -0.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $3.02M | +71.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $65.18B | +44.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $62.58B | -1.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $94.19B | +6.0% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $480.14M | +5.7% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $65.01B | +1.3% |
Compare CNBX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗